Key Takeaways
- FDA advisory committee rejected AstraZeneca’s camizestrant for breast cancer treatment with a 6-3 vote
- Prostate cancer therapy Truqap received favorable 7-1 recommendation from separate panel
- AZN shares declined 1.13% in premarket hours, trading at $185.25
- Analysts at Morgan Stanley cited “regulatory overhang” concerns following advisory vote
- Company maintains confidence in camizestrant’s clinical data despite panel outcome
AstraZeneca received contrasting opinions from FDA advisory committees on Thursday, as regulators evaluated two separate oncology treatments with vastly different outcomes.
Shares retreated 1.13% during premarket hours on Friday, trading at $185.25. The stock has declined approximately 6.9% over the past 30 days, contrasting sharply with the S&P 500’s 9.9% gain during the same timeframe.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) evaluated two cancer medications from AstraZeneca during a single session — delivering markedly divergent recommendations.
In the unfavorable decision, committee members voted 6-3 against recommending camizestrant, an oral therapy designed for first-line treatment of HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations.
Advisory panel members concluded that camizestrant failed to demonstrate “meaningful benefit” for patients whose condition hadn’t yet worsened on existing treatments.
Trial results from the SERENA-6 study demonstrated that camizestrant achieved a 56% reduction in disease advancement or death. The treatment extended median progression-free survival to 16 months, versus 9.2 months observed with current standard therapies.
However, panelists expressed reservations about the completeness of crucial secondary endpoints, particularly overall survival and time to second progression, during the interim data review.
A subsequent pre-planned analysis revealed statistically significant PFS2 improvements — 25.7 months compared to 19.1 months — while overall survival data continued trending favorably for camizestrant.
AstraZeneca expressed disappointment with the committee’s decision but reaffirmed confidence in the clinical evidence and therapeutic potential for patients.
Analyst Warning on Regulatory Uncertainty
Morgan Stanley research team, headed by Sarita Kapila, characterized the outcome as creating “regulatory overhang and a dent to investor sentiment.”
The analysts acknowledged that FDA approval remains within reach, though the 6-3 vote diminishes probability for the SERENA-6 indication. While the FDA maintains independence from advisory recommendations, it generally aligns with panel guidance. A definitive agency ruling is anticipated.
Positive Outcome for Prostate Cancer Treatment
The day brought encouraging news as well. ODAC members voted 7-1 to recommend Truqap (capivasertib), administered alongside abiraterone and androgen deprivation therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer patients.
The favorable recommendation stemmed from Phase 3 CAPItello-281 trial data, demonstrating a 19% decrease in disease progression or death risk.
Median radiographic progression-free survival extended to 33.2 months among Truqap-treated patients, compared with 25.7 months in the control group.
Additional endpoints similarly supported the combination therapy, including postponed progression to castration resistance and enhanced PSA marker responses.
The treatment’s safety characteristics aligned with established profiles for these drug classes, although Grade 3 or higher adverse reactions occurred more frequently with Truqap. Overall survival information continues developing but demonstrates favorable trends for the combination regimen.
AZN remains essentially unchanged year-to-date, while the S&P 500 has advanced 4.8% during the identical period.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
